Core Insights - Profound Medical Corp. reported its second quarter financial results for 2025, highlighting growth in TULSA-PRO system utilization and a strong sales pipeline, despite experiencing short-term delays in capital sales [1][3]. Business Highlights - Utilization of TULSA-PRO systems increased, with "same store" procedure volumes rising by 10% sequentially from Q1-2025 [2]. - The sales pipeline for TULSA-PRO has expanded to 80 new systems in various stages of the sales process [2]. - Patient demographics treated with TULSA-PRO in Q2-2025 included 79% for prostate cancer, 17% for hybrid conditions, and 3% for salvage therapy [2]. - The company hosted an investor event at the AUA 2025, showcasing positive initial data from the CAPTAIN trial, which indicated TULSA's advantages over robotic radical prostatectomy [2]. - Leonard Wheeler was appointed as Global Ambassador for TULSA-PRO to enhance awareness and advocacy [2]. - The TULSA-AI Volume Reduction Module was successfully launched for BPH treatment, with a full launch expected in Q4-2025 [3]. Financial Performance - Revenue for Q2-2025 was approximately $2.2 million, with $1.6 million from recurring non-capital revenue and $650,000 from capital equipment sales [4]. - Gross margin improved to 73% in Q2-2025, up from 64% in the prior year, attributed to higher manufacturing efficiency [5]. - Total operating expenses rose to approximately $15.4 million, compared to $9.3 million in the previous year, driven by increased headcount and trial enrollment [6]. - The net loss for Q2-2025 was approximately $15.7 million, or $0.52 per share, compared to a loss of $6.9 million, or $0.28 per share, in Q2-2024 [7]. Liquidity and Share Capital - As of June 30, 2025, the company had cash reserves of approximately $35.2 million [8]. - The total number of common shares outstanding was 30,053,142 as of August 14, 2025 [8].